BioLargo Inc (OTCQB:BLGO) announced Thursday that Clyraguard, a spray developed by subsidiary Clyra Medical Technologies, was shown to cause complete inactivation of the SARS-CoV-2 virus in lab testing.
Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from SARS-CoV-2, the virus that causes COVID-19.
The product is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining. Testing was conducted under the supervision of Dr Slobodan Paessler at the Galveston National Laboratory at the University of Texas Medical Branch.
READ: BioLargo Inc clocked record revenue in 2019 driven by new channel partnerships, commercial milestones
“We are very proud of the Clyra team for creating this powerful tool to help fight the spread of SARS-CoV-2,” BioLargo CEO Dennis Calvert said. “Clyraguard will help protect people as we continue to fight the spread of the pandemic and will help people get back to living their lives.”
Along with and in addition to its subsidiary Clyra Medical, BioLargo has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination and advanced wound care.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel